Nature Biotechnology, Published online: 27 January 2026; doi:10.1038/s41587-025-02998-xAs pressure mounts globally on drug pricing and development cost continues to rise, clinicians and translational scientists in biotech, academia and biopharma companies are re-evaluating when, where and how to launch early clinical programs. These initial patient data become critical to de-risk development programs and allow developers to deploy their limited time and resources on the most promising drugs…
Read More
About The Author
